Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim

NCT04947618 | Unknown

• 1 other identifier: NIMAO/2019-01/EJ-01
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Observation of a cohort of 400 patients with different types of lymphomas.

Conditions

Lymphoma, Malignant

Keywords

-Lymphoma; Mantle-Cell; Follicular; Hodgkin; T-cell; Primitive Cerebral; Marginal Zone; Waldenström's macroglobulinemia

Outcome Measures

Primary Outcomes (6)

• Overall survival rate among patients with Hodgkin Lymphomas

  The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

  2 years after inclusion

• Overall survival rate among patients with Mantle-cell Lymphomas

  The number of months during which the patient has survived since inclusion will be noted.If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

  2 years after inclusion

• Overall survival rate among patients with Primitive Cerebral Lymphomas

  The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

  2 years after inclusion

• Overall survival rate among patients with Follicular Lymphomas

  The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

  2 years after inclusion

• Overall survival rate among patients with Marginal Zone Lymphomas

  The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

  2 years after inclusion

• Overall survival rate among patients with Waldenström's Disease

  If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

  2 years after inclusion

Secondary Outcomes (18)

• Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.

  2 years after inclusion

• Differences between management of patients with Mantle-cell Lymphomas and data described in the literature.

  2 years after inclusion

• Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature.

  2 years after inclusion

• Differences between management of patients with Follicular Lymphomas and data described in the literature.

  2 years after inclusion

• Differences between management of patients with Marginal Zone Lymphomas and data described in the literature.

  2 years after inclusion

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The population consists of patients with lymphomas (Malignant Non-Hodgkinien and Hodgkin Lymphomas) diagnosed at Nîmes University Hospital from 1999 onwards and for whom the frozen biological samples are available. Since 2005, all patients have been registered in the Tumototek software program. Those diagnosed before this date can be found in the hospital's anatomopathological laboratory registers.

You may qualify if:

• Patients over the age of 15 years and 3 months, diagnosed with lymphoma at Nîmes University Hospital as from 1999 onwards and for whom diagnostic tumor material is available.

You may not qualify if:

• Patients aged 18 or over who have expressed their desire not to take part in the study.
• Patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study.
• Patients under legal guardianship.

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU Nimes

Nîmes, 30029, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Lymphoma protocol was applied. Biopsies of lymphomas used for anatomopathological analysis, frozen and used for cytogenetic analysis if possible.

MeSH Terms

Conditions

Lymphoma; Waldenstrom Macroglobulinemia

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders

Study Officials

• Anissa MEGZARI

  CHU de Nîmes (Nîmes University Hospital)

  STUDY CHAIR

Central Study Contacts

Eric JOURDAN, Dr.

CONTACT

0466684033; eric.jourdan@chu-nimes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2021
• First Posted: July 1, 2021
• Study Start: January 22, 2024
• Primary Completion: January 31, 2026
• Study Completion: January 31, 2026
• Last Updated: January 24, 2024

Record last verified: 2024-01

Locations

FR (1)